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Abstract: Inclusions of lidocaine hydrochloride in cyclodextrins were prepared to obtain stable 
complexes compatible for association with chlorhexidine in a new gel formulation for use in 
urogenital applications. Two cyclodextrins, β-cyclodextrin and methyl-β-cyclodextrin, were 
used for encapsulating lidocaine hydrochloride through solubilization and kneading techniques. 
The lidocaine–cyclodextrin complexes were characterized by ultraviolet spectroscopy, Fourier 
transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffraction. The 
results revealed that the techniques generated good yields of inclusion products that maintained 
the functional properties of lidocaine. In addition, the inclusion products obtained improved the 
compatibility of lidocaine hydrochloride with chlorhexidine in solution and a gel formulation. 
The gel formulation displayed desirable rheological and physicochemical properties. The results 
presented here are the first description of the inclusion of lidocaine with cyclodextrins, which 
improves compatibility with chlorhexidine in formulations for simultaneous delivery.
Keywords: solubilization and kneading inclusion techniques, cyclodextrins, lidocaine 
  hydrochloride, chlorhexidine gluconate incompatibility, urogenital gel formulations
Introduction
The increase in various urogenital procedures, including invasive procedures, has cre-
ated a need for sterile lubricants that also deliver, simultaneously, a local anesthetic 
and a bactericide.1–4 Yet the availability in the pharmaceutical market of products with 
these characteristics is still very low. The British National Formulary describes a gel 
formulation that includes 2% lidocaine hydrochloride (LID, anesthetic) and 0.25% 
chlorhexidine gluconate (CHX, bactericide) together, which is available commercially.5 
However, the characteristics of these drugs together show evidence of physicochemical 
incompatibilities, which suggests that this type of formulation is extremely unstable, 
unless one or both drugs have been modified to avoid such phenomena.6,7
The literature describes several approaches for improving the stability and/or com-
patibility for different drugs such as solvent selection during formulation and molecular 
encapsulation processes.8 Cyclodextrins (CDs) are commonly used for encapsulation 
and comprise a series of α-1,4-linked cyclic oligosaccharides consisting of 6 (αCD), 
7 (βCD), 8 (γCD), or more glucose units leading to a cup-like geometry. CDs have 
a rigid structure with a singular hydrophobic cavity due the absence of hydroxyl 
groups. Due to their distinctive structure, CDs are able to enhance the solubility, 
chemical stability, and bioavailability of poorly soluble drugs, while reducing toxicity International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and controlling the rate of release.9 Moreover, complexing 
drugs with CD may also: i) enhance drug stability to air and 
light, ii) affect the availability of topically applied products, 
either increasing or decreasing their permeability into and 
through the skin, and iii) delay the beginning of the process 
of photodegradation.9–11 In comparison with other phar-
macotechnical approaches, the performance of CDs often 
displays greater efficacy for stabilizing drugs and bridging 
drug incompatibilities in various formulations and, in many 
situations, represents the only alternative.
We investigated the inclusion of LID into CDs to create 
a new urogenital gel formulation together with CHX with 
increased stability and an adequate release profile. Towards 
that purpose, LID and the CDs β-cyclodextrin (βCD) and 
methyl-β-cyclodextrin (MβCD) were tested by using solu-
bilization and kneading techniques. The LID–CD inclusion 
complexes were characterized and the gel formulated with 
these complexes was evaluated for the in vitro release of LID 
from the complex, its rheological properties, and other pharma-
cotechnical properties for characterization of a new formula-
tion for delivery of an anesthetic together with a bactericide.
Material and methods
Materials
Ethanol (95%), butylated hydroxyanisole (BHA) and buty-
lated hydroxytoluene (BHT), Nipagim, polyethylene glycol 
(PEG) 6000, PEG-15 cocopolyamine, and Natrosol were 
obtained from DEG (São Paulo, Brazil); the CHX standard 
(20% w/v) was obtained from Sigma-Aldrich (St Louis, MO); 
LID was obtained from Nortec Química (Xerém, RJ, Brazil); 
and βCD and MβCD were obtained from Wacker-Chemie 
GmbH (Munchen, Germany) and were of a pharmaceutical 
grade. The purified water used in all solutions preparations was 
prepared using a Milli-Q system (Millipore, Billerica, MA).
Drug and formulation analysis
The concentration of LID and CHX was determined follow-
ing the protocols outlined by the Brazilian Pharmacopoeia 
(1998).12 Other tests used to assess the quality of raw mate-
rials followed the guidelines of the Brazilian and British 
Pharmacopeia monographs.12,13
Apparatus and chromatographic 
conditions
A high performance liquid chromatograph (HPLC) model 
Shimadzu LC-10AT was used. The chromatographic condi-
tions were initially based on a study of simultaneous deter-
mination of LID and CHX in a triamcinolone acetonide 
suspension, using reverse phase HPLC.14 During the veri-
fication of the best chromatographic conditions to resolve 
the peaks of each drug using known standards, the mobile 
phase was varied between 60% and 65% of methanol with 
  triethylamine (0.4%) at pH 3.5 and the detection wavelength 
was set at 240 nm. Experimental samples were analyzed 
based on those conditions.
Preparation of standard and sample 
solution
A working standard solution of LID and CHX in mobile phase 
(400 µg/mL for LID and 50 µg/mL for CHX) was prepared 
using drug reference standard from US Pharmacopeia that 
was accurately weighed and transferred into a 50-mL flask. 
Mobile phase was added to the mixture and sonicated until the 
standard dissolved completely (∼5 minutes). Then the flask 
was filled with mobile phase and filtered through a 0.45 µm 
membrane filter (Millipore).
For sample preparation, an adequate amount of gel for-
mulation or chemical standard substances were weighed and 
the amount equivalent to 400 µg/mL of LID and 50 µg/mL 
for CHX were transferred to a 50 mL volumetric flask. After 
that, the preparation followed the same procedure described 
for the standard solution preparation.
Validation of HPLC quantitative  
determination of LID and CHX
In order to validate the analytical method proposed, the mea-
surement parameters were investigated for linearity, accuracy, 
precision, and specificity according to the International 
Conference on Harmonization recommendations.15
Linearity was tested with a range of concentrations 
(50%, 80%, 100%, 120%, and 150%); 100% corresponded 
to a concentration of 400 µg/mL for LID and 50 µg/mL for 
CHX. A calibration curve was generated and the linearity 
was evaluated by the calculated correlation coefficient and 
interception value.
Accuracy was evaluated by analyzing 3 independently 
prepared samples (spiked placebo) of 3 concentrations 
(80%, 100%, and 120% of the working concentration). Each 
preparation was measured 3 times. Values between 98% and 
102% of recovery were considered acceptable.
Precision of the measurement method was determined by 
evaluating the repeatability and the intermediate precision 
of measurements on standards. Repeatability was evaluated 
using 6 replicated samples of a solution containing drugs 
at a concentration of 100% of the regular analytical work-
ing concentration.15 The intermediate precision was judged International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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by repeating the procedure on 2 different days. The results 
obtained were analyzed statistically and a RSD value below 
2% was considered acceptable.
Specificity was determined with Class VP software, 
which calculated the peak purity by ratiogram. The specific-
ity was further analyzed by comparing the chromatograms 
of the various formulations to the placebo chromatogram 
for evidence of interference from the formulation matrix on 
the measurements.
Formulation of LID and CHX gel 
formulations
Initially, LID and CHX were prepared in a range of ethanol 
solutions (10%, 30%, 50%, 70%, and 90%) to obtain final 
concentrations of 2.0% w/v for LID and 0.25% w/v for CHX. 
Complete solubilization of the drugs was observed. The 
compatibility of the 2 drugs was evaluated by maintaining 
solutions in a 10-mL beaker under magnetic stirring for 0, 
5, 30, and 60 minutes, and 24 hours and observing turbidity. 
The presence of white precipitate was considered evidence 
of incompatibility.
The gel formulation preparation was initiated by choosing 
the ideal excipients based on compatibility with the drugs, 
especially for CHX. The tests for the carrier solutions were 
performed according to the procedures described above with 
a concentration of 0.25% w/v for CHX. After the compatible 
excipient was determined, the gel was formulated by adding 
methylparaben and BHA to a final concentration of approxi-
mately 40% w/v under magnetic stirring. Then, PEG-15 
cocopolyamine was added to a concentration of 2%. After 
incorporation, hydroethylcellulose (4%) and the remaining 
water were added. This mixture was kept under magnetic stir-
ring until complete gelation of the polymer and a final gel that 
was mostly clear with a slight yellow tint due to the presence 
of hydroxyethylcellulose and PEG-15 cocopolyamine. For a 
gel containing ethanol, BHA was substituted with BHT at 
the same concentration.
Preparation of LID–CDs complexes  
through the solubilization method
To establish the optimal ratio of LID with βCD and MβCD,16–18 
stock solutions of the CDs (1.15 g diluted in 100 mL of 
purified water) and LID (50 mg dissolved in 5 mL solvent) 
were prepared separately. LID was then added to the vessels 
containing the CD solution (qs 20 mL) in volumes necessary 
to reach various CD:drug molar ratios (2:1, 3:1, 4:1, 5:1, 6:1, 
and 7:1). For control purposes, a “0” point including only 
the original LID solution without CD was also prepared. 
All mixtures were stirred for 72 hours at 25°C followed by a 
time without stirring to allow   precipitates to settle, and then 
decanted through Whatman 42 analytical paper. If no addi-
tional precipitate was observed, the inclusion products were 
frozen at -70°C and lyophilized for further analysis.
Inclusion of LID into CDs by kneading 
method
The calculated amounts of drug and corresponding CD 
were weighed, and moistened with a small volume (1 mL) 
of ethanol:water solution (70:30, v/v). The mixtures were 
grounded using a ball mill until the mixture reached a granu-
lation aspect.16 The resulting product was further mixed for 
30 minutes. The final samples were dried in an oven at 55°C 
for 30 minutes and stored in desiccators.
Characterization of the inclusion 
complexes
The concentrations of LID in the CD complex were determined 
by using an UV spectrometer (Perkin-Elmer, Norwalk, CT). 
The concentrations in the calibration curve were 2.0, 4.0, 6.0, 
8.0, 10.0, and 12.0 µg/mL for LID, with R2 values between 
0.995 and 0.998 in all of the studied cases. Fourier trans-
formed infrared spectra for all samples were recorded using 
KBr pellets (1 mg sample per 300 mg KBr) on a Perkin-Elmer 
FT-IR Spectrometer Paragon 1000 grating instrument with 
slow scan and normal slit width: X-ray diffraction patterns 
of the drug–CD inclusion complex were obtained by using 
an X-ray Diffractometer (XRD; Rigaku, Tokyo, Japan). The 
diffraction angle (2θ) of the patterns was recorded from 2° 
to 10° at 1°/min, with a total scanning speed of 41 minutes. 
CuKa radiation was used as the X-ray source, which was 
operated at 40 kV and 30 mA at room temperature and 
0.15418 nm wavelength. Differential scanning calorimeter 
analysis was performed from 0°C to 400°C (10°C/min) with 
a Perkin-Elmer DSC 7 in an aluminum pan under a nitrogen 
flow (22.5 mL/min).
Stability studies
The stability of the prepared gels was determined using each 
of the analytical methodologies previously described for the 
drug assays and also included pH and rheological proprieties. 
Samples were stored under 30 ± 2°C and 75% ± 5% RH for 
30, 60, and 90 days. The pH of the samples was determined 
using a Digimed DM21 potentiometer. The rheological study 
was performed to obtain the physical parameters such as flow 
index, consistency index, apparent viscosity and thixotropy. 
Rheological measurements were obtained in an Advanced International Journal of Nanomedicine 2011:6
Table 1 Chromatographic analysis conditions for chlorhexidine 
gluconate (CHX) and lidocaine hydrochloride (LID)
Chromatographic 
conditions
Specifications
Column Shim-pack CLC – ODS 250 × 4.6 mm, 5 µm
Elution Isocratic
Mobile phase 63:37 
Methanol; purified water with triethylamine  
0.4%; pH 3.5
Flow 0.8 mL/min
Run time 20 min
Wavelength (λ) 240 nm
Injection volume 20 µL
Diluent Mobile phase
Temperature Room temperature
Abbreviations: CLC-ODS, Capillary liquid chromatography-octadecylsilane
submit your manuscript | www.dovepress.com
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Rheometer (TA Instruments, New Castle, DE), model 2000, 
which is a cone and plate viscosimeter with a 60 mm cone and a 
2° determination angle. Samples (3.0 g) were placed on the hot 
plate at 37°C and the cone rotates under adjustable speeds.
In vitro drug release analysis
The release of LID from the CD complexes and the gel for-
mulation was evaluated in vitro using a modified apparatus 
based on the Franz Cell concept.19,20 An acetate cellulose 
membrane was mounted on a diffusion system and a sample 
containing 200 mg of LID was introduced into the donor 
compartment. Sink conditions were met in all cases and 
6 parallel determinations were performed at 37 ± 0.5°C. 
Aliquots of the acceptor solution were withdrawn after 5, 20, 
40, 60, 90, 120, 180, 240, 300, and 360 minutes. A volume 
of medium equal to that withdrawn was added back fol-
lowing each sampling. The collected fractions were filtered 
through a 0.45-mm membrane and the filtrate was analyzed 
by HPLC to quantify the amount of drug diffused into the 
acceptor solution using a standard curves with a range of 
10% to 110% prepared in the same day.
The cumulative amount of drug released through the 
membrane was plotted as a function of time. The flux values 
(J) was calculated from the slopes of the linear portion (steady 
state) of in vitro release curves. Release kinetics were deter-
mined by linear regression analysis by applying 3 models: 
zero order, Higuchi, first order, and Peppas.
Statistical data analysis
One-way ANOVA and Wilcoxon match pair tests were used 
to analyze all of the data obtained.
Results and Discussion
Methods development and optimization
The isocratic-mode method with UV detection applied in 
this study was developed for the determination of the active 
ingredients, LID and CHX, at the 100% level, and its main 
degradation products, p-chloroaniline and 2,6-dimethylaniline. 
Towards that purpose, a reversed-phase column C18 (250 mm, 
4.0 mm; 5.0 µm) was used and tested with mobile phases 
consisting of methanol concentrations of 60%, 62%, 63%, 
and 65% with 0.4% triethylamine solutions at various ratios 
(65:35; 63:37; 62:38, and 60:40, v/v). The variation in the 
methanol concentration of the mobile phase significantly 
modified the CHX retention time, but not the LID retention 
time, which remained mostly unchanged. An increase in the 
methanol concentration from 60% to 65% in the mobile phase 
decreased the CHX retention time from 14.5 to 6.4 minutes. 
The addition of triethylamine to the mobile phase generated an 
improved symmetry of the observed chromatographic peaks 
for both drugs without an alteration in the retention time or 
the separation of the peaks. Variations in the pH of the mobile 
phase from 3.0 to 4.0 did not significantly alter the drug reten-
tion time, but affected the shape of the peak for CHX. By 
comparing the chromatographic behavior as peak retention 
times, theoretical plates, capacity, and tailing factors, the chro-
matographic conditions described in Table 1 were considered 
ideal. Under the preferred conditions, LID displayed a retention 
time of 4.4 minutes, a theoretical plate of 3961, and an asym-
metry of 1.66. For CHX, the retention time was 10.1 minute 
with a theoretical plate of 6707 and an asymmetry of 1.47. The 
literature described similar results from the analysis of another 
gel formulation, but with different excipients.14
Method validation
The selectivity of the assay method for the drug determi-
nation and for the presence of CHX degradation products 
(p-chloroaniline and 2,6-dimethylaniline) in the formulation 
was accessed by individual chromatograms obtained for each 
drug with the formulation matrix and revealed an adequate 
peak purity for the drugs (Figure 1).
The linearity was determined using 5 samples in different 
concentrations between 50% and 150% from the nominal 
assay concentration of 400 µg/mL for LID and 50 µg/mL for 
CHX standard. This procedure was carried out on 2 different 
days in agreement to the ICH.15 A calibration curve was con-
structed to calculate the correlation coefficient and intercept 
value, which was evaluated using a statistic study (ANOVA) 
and determined to be significant (P , 0.05). The regression 
equation was obtained by a least squares treatment of the 
data and the results confirmed the linearity of the data from 
the method developed (Table 2). The homoscedasticity of the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 Chromatograms of placebo contaminated with LID, CHX, and degradation products (p-chloroaniline and 2,6-dimethylaniline) A) and the respective 3D UV/Vis 
spectra B).
Abbreviations: CHX, chlorhexidine gluconate; LID, lidocaine hydrochloride.
calibration curves was tested using Cochran’s test (G = largest 
variance/sum of variances).21 The G value obtained in this 
study (0.419) was smaller than the critical value (G = 0.684), 
indicating that variances were not significantly different.
The accuracy was evaluated by the recovery of CHX and 
LID at 3 different levels (80%, 100%, and 120%), tested 
3 times. The individual recoveries ranged from 99.6% to 
100.4% for LID and 98.1% to 100.7% for CHX with an 
RSD , 1.5% in both cases. Therefore, these results indicate 
the accuracy of the method for determination of both drugs.
The reproducibility of the methods was confirmed by 
analyzing 3 sample replicates on the same equipment with a 
concentration that ranged from 80% to 120% of the analyti-
cal concentration (100%). The intermediate precision was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1148
Soares da Silva et al
Table 2 Summary data of linearity for HPLC method
Parameters LID CHX
Slope (b)   7015394 ± 17427.4 54433871 ± 617649.2
Intercept (a) 191754.5 ± 1727.5 -285845 ± 4358.6
r 0.99925 ± 0.00007 0.9975 ± 0.0004
Note: Media ± standard deviation of n = 2 determinations.
Abbreviations: CHX, chlorhexidine gluconate; LID, lidocaine hydrochloride.
Table 3 Summary data of repeatability and intermediate precision
LID CHX
Level  
(%)
Day Area Repeatability  
RSD (%)
Intermediate  
precision RSD (%)
Area Repeatability 
RSD (%)
Intermediate  
precision RSD (%)
80 1 2761547 0.94 1.61 2049852 1.65 1.76
2813985 2079847
2787451 2012487
2 2683619 1.35 1974800 1.36
2744241 2015078
2749893 2026612
100 1 3102148 0.45 1.39 2493331 0.51 0.35
3085497 2518528
3074812 2502487
2 3108475 1.47 2496134 0.19
3195874 2501924
3125489 2505560
120 1 3708974 1.22 1.11 2981971 0.47 1.22
3694751 2993257
3624871 2965487
2 3648719 1.19 2895748 0.88
3619875 2930154
3705481 2945817
Abbreviations: CHX, chlorhexidine gluconate; LID, lidocaine hydrochloride; RSD, Relation Standard Deviation.
determined by performing the analysis on 2 different days. 
The data presented in Table 3 show that the method has a 
good repeatability and intermediate precision.
The detection limit was 2.7 µg/mL for LID and 0.6 µg/mL 
for CHX, while the quantification limit was 9.0 µg/mL for 
LID and 2.1 µg/mL for CHX. These values were calculated 
using calibration curves generated from a range of concentra-
tions between 50% to 150% of each drug (200 to 600 µg/mL 
for LID and 25 to 75 µg/mL for CHX).
CHX and LID gel formulation 
development
Initially, the compatibility of CHX and LID together in 
solution was investigated. CHX and LID are known to 
be incompatible in the presence of different ions and 
hydrochlorides leading to precipitation and degradation, 
but unknown in a simple hydroalcoholic solution. The 
result of degradation is the formation of various amounts 
of p-chloroaniline, which was described previously.6,22,23 
Ethanol was chosen as the solvent because of its utiliza-
tion in various gels formulas. The increase of ethanol in 
the mixture up to 75% did not prevent the precipitation. 
An immediate precipitation was observed when using 0.5% 
ethanol and, with a delay up to 24 hours, when using 95% 
ethanol. Therefore, even in a less polar solvent, which 
effectively dissolved less LID, incompatibility between the 
drugs was observed. This observation contradicts the report 
by Abdelmageed and Colleagues24 which described a stable 
relationship within a formulation (trade name Instilliagel®) 
with morphine sulfate, which was prepared for clinical 
studies.24 Our results demonstrating an incompatibility 
between LID and CHX in solvents normally capable of 
dissolving the drugs individually suggested the need for an 
alternative approach to prevent the formation of precipitate 
and a break-down of the drugs.
The alternative approach was to complex one of the drugs 
into CDs. LID was chosen since it is less soluble and smaller 
then CHX, increasing the chance of a total inclusion into the 
CD cavity. The inclusion of CHX and LID into CD has been 
previously described, but only for the free base and not for 
the salt forms of these drugs.25,26 To complex the salt form of 
LID, βCD and MβCD were investigated for their ability to 
form LID inclusion complexes. The stability constant of the 
inclusion complex was determined by solubilization method 
with different concentration of CDs, emphasizing that LID 
solution absorbance is near to zero, differentiating the inclu-
sion complex obtained. The correlation between the observed 
absorbance depended on the concentration of βCD added 
to the LID that was previously solubilized in the medium 
and was linear with a correlation coefficient of 0.9996. The International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table  4  Results  of  the  compatibility  study  of  free  drugs  in 
aqueous media comparing inclusion complexes during 10 days
Parameter Drug free CHX +  
LID–βCD
CHX +  
LID–MBβCD
Turbidity Presenta Absent Absent
Precipitation Presenta Absent Absent
Content of CHX  
mean ± SD  
(g/100 mL)
0.015 ± 0.0007 0.258 ± 0.001 0.259 ± 0.003
Content of LID  
mean ± SD  
(g/100 mL)
1.933 ± 0.005 1.944 ± 0.01 1.970 ± 0.02
Note: aTurbidity and precipitation in solution occurred in about 5 minutes. Study 
performed at room temperature.
Abbreviations:  βCD,  β-cyclodextrin;  CD,  cyclodextrin;  CHX,  chlorhexidine 
gluconate; LID, lidocaine hydrochloride; MβCD, methyl-β-cyclodextrin; SD, standard 
deviation.
Table 5 Formula proposed for the new LID and CHX gels and description of the functional classification of each excipient
Excipient Excipient functionality/content (%) Characteristics
Butylhydroxytoluene Antioxidant/0.05 Soluble in water and compatible with the drugs
Methylparaben Preservative/0.1 Soluble in water and compatible with the drugs
PEG 6000 Thickener/2.0 Soluble in water and compatible with the drugs
PEG-15 cocopolyamine Mucoadhesive/2.0 Soluble in water and compatible with the drugs
Hydroxyethylcellulose Gelling/4.0 Gels in aqueous solution and is compatible with the drugs
Abbreviations: CHX, chlorhexidine gluconate; LID, lidocaine hydrochloride; PEG, polyethylene glycol.
calculated stability constant (K) of the complexed LID with 
βCD was 34954.1 ± 995.4 M-1. For the solution using MβCD, 
the correlation absorbance concentration was also linear with 
a coefficient of 0.9955. The calculated stability constant of 
the complex LID–MβCD was 5565.3 ± 819.9 M-1. These 
values are considered high compared with those previously 
reported, indicating a stabile complex of LID with both ßCD 
and MßCD.27 Despite the variations observed, the water solu-
bility observed for both complexes indicates their feasibility 
in formulating theses complexes as gels at a concentration 
of 2.0% w/w, which translates to values of 24.95 mg/mL 
for LID–βCD and 131.56 mg/mL for LID–MβCD at room 
temperature. The solubility of the inclusion complexes in 
aqueous medium was lower than LID alone (166.4 mg/mL), 
which can be seen with the inclusion of very water soluble 
molecules.26,28–30 In ethanol, the extent of solubility observed 
ruled out the possibility of obtaining gel formulations of 2.0% 
w/w for the molecules under study.
The kneading process was also attempted for the inclu-
sion of LID with CDs due to the industrial feasibility of 
this technique. From the experimental determination of the 
stability constants, LID was included into βCD and MβCD 
at a 1:1 CD:drug ratio. The kneading method is described in 
the literature as an easy procedure, with low cost and high 
reproducibility.11 Using this technique, the results showed 
a successful inclusion process with about 100% yield for 
βCD and MβCD as measured by LID extraction and HPLC 
analysis.
The XRD patterns of LID demonstrated that the physical 
mixtures and inclusion complexes in βCD and MβCD had 
a progressive loss of crystallinity in the complex, which 
demonstrated the phenomenon of inclusion (Figure 2). 
The infrared analysis of the inclusion products showed 
LID present in the sample. However the infrared spectra of 
inclusion complex and physical mixture were quite similar. 
The major difference was the amine bands of LID (1650 
and 1550 cm-1) present in the spectrum of physical mixture 
that disappear in the spectrum of the inclusion complex. 
The analysis of the inclusion products using DSC revealed 
the formation of the inclusion complex by the disappear-
ance of the fusion endotherm of LID (127–129°C) with the 
concomitant maintenance of the dehydration endotherms at 
around 158°C and 300°C, typical of MβCD (Figure 3). As 
reported in the literature, the ethanol competition with the 
guest molecule could also interfere in the formation of the 
inclusion complex, which strengthens the preferential use 
of water as solvent.31
The compatibility of the LID inclusion complexes with 
CHX was evaluated by the preparation of an aqueous solution of 
LID at 2.0% w/w or its equivalent within inclusion   complexes 
with βCD or MβCD mixed with CHX at 0.25% w/w. Both 
complexes of LID showed an absence of turbidity over a 
24-hour period. The noncomplexed control, consisting of an 
aqueous solution of LID in the presence of CHX, displayed 
turbidity and precipitation within 3 minutes. Over a 10-day 
period with agitation at room temperature, extensive precipita-
tion was observed in control solutions. Solutions containing 
LID complexed with CDs maintained equivalent levels of 
CHX in filtrates after filtration, as seen in Table 4. These data 
clearly demonstrate that the inclusion of LID with CD effec-
tively stabilized the presence of CHX in solution over time 
and permitted both drugs to be present together.
The higher solubility in water observed for the LID com-
plexed with MβCD was the deciding factor to utilize these 
complexes to formulate a new gel. Three ingredients of each International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Table 6 Assay of drugs in the proposed formulation at time zero 
and after 6 months
Time LID content (%)a CHX content (%)a
0 98.8 ± 0.04 99.6 ± 0.002
6 months 98.6 ± 0.04 99.3 ± 0.001
Note: aMedia ± standard deviation of n = 3 determinations.
Abbreviations: CHX, chlorhexidine gluconate; LID, lidocaine hydrochloride.
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Figure 4 Amount of lidocaine hydrochloride A) and chlorhexidine gluconate B) released (µg/cm2) versus time (hours) from the proposed formulation (n = 12).
functional category needed for gel formation were tested for 
their compatibility with the drugs in aqueous solution and 
their compatibility percentages defined. These complexes 
were soluble or miscible with the additives, with no turbidity 
or precipitation observed in the solutions after 10 days under 
agitation. Table 5 presents the basic composition proposed 
for the formulation of the gel.
The final gel presented a slightly yellowish color and 
an LID content of 98.8% ± 0.04% and a CHX content of 
99.6% ± 0.002%. The pH measured was 5.8, close to the 
optimum pH for a vaginal cream (3.5–4.5). The pH of greater 
stability for the drugs is between 3 and 6.6,32 An excellent 
stability was observed for the new formulation (Table 6), 
indicating its strong commercial viability.
In release studies, purified water was used as the acceptor 
solution.33–35 The CHX solubility determined in this medium 
was 200 mg/mL, and for LID 166.4 mg/mL. In order to ensure 
sink conditions, the volume of acceptor solution was fixed at 
20.0 mL. The sink condition was considered satisfactory since 
the drug concentrations in this medium was at least 10 times 
smaller than the experimental drug solubility, considering International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 7 Rheogram of the proposed formulation showing the elastic modulus G′ 
(diamond) and viscosity modulus G″ (square) versus frequency from 0.1 to 10.0 Hz 
with a fixed percentage of deformation.
Table 7 Cumulative amounts of LID and CHX released from the 
formulation proposed in function of time in vitro release studies
Time (min) Cumulative amounts released (μg/cm2)
LIDa CHXa
5 35.7 ± 6.5 0.24 ± 0.13
20 81.2 ± 6.2 2.31 ± 0.20
40 111.9 ± 5.9 5.22 ± 0.27
60 123.8 ± 6.3 6.11 ± 0.38
90 137.3 ± 5.9 7.29 ± 0.36
120 144.7 ± 5.9 8.99 ± 0.44
Note: aMedia ± standard deviation of n = 3 determinations.
Abbreviations: CHX, chlorhexidine gluconate; LID, lidocaine hydrochloride.
that all drugs in the donor compartment were released. 
Figure 4 and Table 7 show the in vitro release profiles over 
6 hours using the formulations proposed. The results demon-
strated that the drugs were released from the formulation. The 
release kinetics followed the Higuchi model (r . 0.99). The 
flux (J) was calculated from the slopes in the linear portion 
of the curves and was 6.196 ± 0.49 µg/cm2 ⋅ min-1 for LID 
and 1.0 ± 0.06 µg/cm2 ⋅ min-1 for CHX.36
Appropriate rheological properties were observed for the 
gel proposed, especially in terms of its ability to spread and 
to coat the urogenital mucosa.37 The rheograms presented in 
Figures 5 and 6 show that the formulation behaved as a non-
Newtonian pseudoplastic fluid. The profiles of the rheograms 
showed an increase in shear stress with an increasing shear 
rate (0.1 to 100 s-1) and a reduction of tension by reducing 
this rate (100 to 0.1 s-1). Both present a nonlinear curve 
profile with a tendency to decrease the apparent viscosity of 
the formulation as a function of increasing shear rate. The 
classification of the formulation as a non-Newtonian fluid 
determines that the interactions between its components 
affect the rate of deformation caused by external forces, 
resulting in no proportionality between the rate (γ) and shear 
stress (τ), as shown in Figure 5.38
The behavior exhibited by the new formulation corre-
sponds to that obtained by Owen et al testing some commercial 
vaginal contraceptive gels.39 These gels, when subjected to 
rheological studies, were characterized as a non-Newtonian 
pseudoplastic fluid due to reduced viscosity of the formulation 
prepared against the increase of shear rate. By observing the 
flow index (n) of the formulation, which indicates the degree 
of resistance during the fluid flow, we measured a value of 
0.4084, which corresponds to a pseudoplastic formulation. 
The consistency index obtained was 151.4 Pa ⋅ sn. These values 
of flow index and consistency index are consistent with those 
of the commercial contraceptive gels previously reported.39
The rheograms shown in Figure 7 demonstrate the 
  dependence behavior of elastic modulus (G′) and viscous mod-
ulus (G″) in relation to frequency, ranging from 0.1 to 10.0 Hz 
with strain rate set at 5%, characterized as a pseudogel.
Figure 8 describes the behavior of the apparent viscosity 
of the formulation over time when the shear rate was fixed at 
10.0 s-1. The significant decrease in viscosity during the initial 
30 seconds, with a relative standard deviation of 4.52%, and 
the profile of this constant from the 30-second test with a 
standard deviation of 1.18%, provided further evidence to 
characterize the formulation as nonthixotropic.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Conclusion
The analytical methodology presented here was validated 
for linearity, selectivity, precision, sensitivity, and accuracy 
to assure its suitablity for use in quantifying the concen-
trations of LID and CHX in the various formulations and 
their release from complexes in vitro. We conclude that 
LID and CHX are incompatible when present together in 
aqueous media. We circumvented this incompatibility by 
the inclusion of LID in MβCD, which enabled the formula-
tion of a gel that presents both an analgesic and bactericide 
simultaneously. The inclusion of 2 mucoadhesive agents, 
hydroxyethylcellulose and PEG-15 cocopolyamine, creates 
a novel gel suitable for application to the physiological 
conditions of the urogenital cavities. The results presented 
here represent the first description of the inclusion of a 
salt of lidocaine into CDs, which points to the potential 
use of this technology in various other pharmacotechnical 
applications.
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